Product Surveillance, Postmarketing

"Product Surveillance, Postmarketing" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

Surveillance of drugs, devices, appliances, etc., for efficacy or adverse effects, after they have been released for general sale.

Descriptor ID	D011358
MeSH Number(s)	E05.337.800
Concept/Terms	Product Surveillance, Postmarketing Product Surveillance, Postmarketing Product Surveillance, Post-Marketing Post-Marketing Product Surveillance Post-Marketing Product Surveillances Product Surveillance, Post Marketing Product Surveillances, Post-Marketing Surveillance, Post-Marketing Product Surveillances, Post-Marketing Product Evaluation Studies, Postmarketing Evaluation Study, Postmarketing Postmarketing Evaluation Studies Postmarketing Evaluation Study Studies, Postmarketing Evaluation Study, Postmarketing Evaluation Postmarketing Product Surveillance Postmarketing Product Surveillances Product Surveillances, Postmarketing Surveillance, Postmarketing Product Surveillances, Postmarketing Product Drug Surveillance, Postmarketing Drug Surveillance, Postmarketing Drug Surveillances, Postmarketing Postmarketing Drug Surveillance Postmarketing Drug Surveillances Surveillance, Postmarketing Drug Surveillances, Postmarketing Drug

Below are MeSH descriptors whose meaning is more general than "Product Surveillance, Postmarketing".

Analytical, Diagnostic and Therapeutic Techniques and Equipment [E]
Investigative Techniques [E05]
Evaluation Studies as Topic [E05.337]
Product Surveillance, Postmarketing [E05.337.800]

Below are MeSH descriptors whose meaning is related to "Product Surveillance, Postmarketing".

Below are MeSH descriptors whose meaning is more specific than "Product Surveillance, Postmarketing".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Product Surveillance, Postmarketing" by people in this website by year, and whether "Product Surveillance, Postmarketing" was a major or minor topic of these publications.

Bar chart showing 8 publications over 7 distinct years, with a maximum of 2 publications in 2010

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
1994	0	1	1
2008	1	0	1
2010	0	2	2
2012	0	1	1
2017	0	1	1
2018	0	1	1
2019	1	0	1

Below are the most recent publications written about "Product Surveillance, Postmarketing" by people in Profiles.

Huybrechts KF, Kulldorff M, Hernández-Díaz S, Bateman BT, Zhu Y, Mogun H, Wang SV. Active Surveillance of the Safety of Medications Used During Pregnancy. Am J Epidemiol. 2021 06 01; 190(6):1159-1168.

View in: PubMed
Colombo A, Chandrasekhar J, Aquino M, Ong TK, Sartori S, Baber U, Lee M, Iniguez A, Hajek P, Borisov B, Atzev B, Den Heijer P, Coufal Z, Hudec M, Mates M, Snyder C, Moalem K, Morrell D, Elmore F, Rowland S, Mehran R. Safety and efficacy of the COMBO bio-engineered stent in an all-comer PCI cohort: 1-Year final clinical outcomes from the MASCOT post-marketing registry. Int J Cardiol. 2019 05 15; 283:67-72.

View in: PubMed
de Winter RJ, Chandrasekhar J, Kalkman DN, Aquino MB, Woudstra P, Beijk MA, Sartori S, Baber U, Tijssen JG, Koch KT, Dangas GD, Colombo A, Mehran R. 1-Year Clinical Outcomes of All-Comer Patients Treated With the Dual-Therapy COMBO Stent: Primary Results of the COMBO Collaboration. JACC Cardiovasc Interv. 2018 10 08; 11(19):1969-1978.

View in: PubMed
Wang SV, Jin Y, Fireman B, Gruber S, He M, Wyss R, Shin H, Ma Y, Keeton S, Karami S, Major JM, Schneeweiss S, Gagne JJ. Relative Performance of Propensity Score Matching Strategies for Subgroup Analyses. Am J Epidemiol. 2018 08 01; 187(8):1799-1807.

View in: PubMed
Mariette X, Förger F, Abraham B, Flynn AD, Moltó A, Flipo RM, van Tubergen A, Shaughnessy L, Simpson J, Teil M, Helmer E, Wang M, Chakravarty EF. Lack of placental transfer of certolizumab pegol during pregnancy: results from CRIB, a prospective, postmarketing, pharmacokinetic study. Ann Rheum Dis. 2018 02; 77(2):228-233.

View in: PubMed
Wang SV, Schneeweiss S, Maclure M, Gagne JJ. "First-wave" bias when conducting active safety monitoring of newly marketed medications with outcome-indexed self-controlled designs. Am J Epidemiol. 2014 Sep 15; 180(6):636-44.

View in: PubMed
Gagne JJ, Wang SV, Rassen JA, Schneeweiss S. A modular, prospective, semi-automated drug safety monitoring system for use in a distributed data environment. Pharmacoepidemiol Drug Saf. 2014 Jun; 23(6):619-27.

View in: PubMed
Thadani U. Should ranolazine be used for all patients with ischemic heart disease or only for symptomatic patients with stable angina or for those with refractory angina pectoris? A critical appraisal. Expert Opin Pharmacother. 2012 Dec; 13(17):2555-63.

View in: PubMed
Diehl DL, Tierney WM, Adler DG, Conway JD, Farraye FA, Kantsevoy SV, Kaul V, Kethu SR, Kwon RS, Mamula P, Pedrosa MC, Rodriguez SA. The role of the U.S. Food and Drug Administration in device evaluation and monitoring. Gastrointest Endosc. 2010 Jul; 72(1):5-10.

View in: PubMed
Block SL, Brown DR, Chatterjee A, Gold MA, Sings HL, Meibohm A, Dana A, Haupt RM, Barr E, Tamms GM, Zhou H, Reisinger KS. Clinical trial and post-licensure safety profile of a prophylactic human papillomavirus (types 6, 11, 16, and 18) l1 virus-like particle vaccine. Pediatr Infect Dis J. 2010 Feb; 29(2):95-101.

View in: PubMed

People

Explore

Similar Concepts

Top Journals